Brought to you by 
Covidien's Mallinckrodt to sell Nuvo's Pennsaid; rights returned
13 Nov 2014
Executive Summary
Drug delivery company Nuvo Research has granted Covidien's Mallinckrodt subsidiary (branded and generic pharmaceuticals) exclusive rights to market its topical diclofenac formulations Pennsaid and Pennsaid Plus in the US.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
- Transdermal
-
Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Covidien's Mallinckrodt to sell Nuvo's Pennsaid; rights returned
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice